These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37314825)
21. Ignoring the Experts: Implications of the FDA's Aduhelm Approval. Maulden A Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585 [TBL] [Abstract][Full Text] [Related]
23. FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease. Tanzi RE ACS Chem Neurosci; 2021 Aug; 12(15):2714-2715. PubMed ID: 34259498 [No Abstract] [Full Text] [Related]
24. Update: FDA approval of Biogen's aducanumab. Hollmann P Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638 [No Abstract] [Full Text] [Related]
25. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia? Gleason A; Ayton S; Bush AI Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902 [No Abstract] [Full Text] [Related]
26. Controversial Approval of New Drug to Treat Alzheimer's Disease. Aschenbrenner DS Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982 [TBL] [Abstract][Full Text] [Related]
27. FDA approves galantamine for Alzheimer's disease. Thompson CA Am J Health Syst Pharm; 2001 Apr; 58(8):649. PubMed ID: 11329755 [No Abstract] [Full Text] [Related]
29. From proposal to patient: how CMS makes coverage decisions. Turnbull GB Ostomy Wound Manage; 2002 Apr; 48(4):8-10, 82. PubMed ID: 11993063 [No Abstract] [Full Text] [Related]
30. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval? Barold HS Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272 [TBL] [Abstract][Full Text] [Related]
32. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab. Rabinovici GD N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284 [No Abstract] [Full Text] [Related]
33. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made? Kurkinen M; Tran L J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888 [No Abstract] [Full Text] [Related]
34. FDA is criticised for licensing high dose donepezil. Lenzer J BMJ; 2011 May; 342():d3270. PubMed ID: 21613347 [No Abstract] [Full Text] [Related]
35. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain. Chambers JD; May KE; Neumann PJ Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986 [TBL] [Abstract][Full Text] [Related]
36. Include Payers in Your Product Development and Clinical Use Processes. Schaum KD Adv Wound Care (New Rochelle); 2020 Nov; 9(11):632-635. PubMed ID: 32311305 [TBL] [Abstract][Full Text] [Related]
37. Aduhelm, the Newly Approved Medication for Alzheimer Disease: What Epidemiologists Can Learn and What Epidemiology Can Offer. Glymour MM; Weuve J; Dufouil C; Mayeda ER Am J Epidemiol; 2022 Jul; 191(8):1347-1351. PubMed ID: 35388413 [TBL] [Abstract][Full Text] [Related]
38. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease. Zissimopoulos J; Jacobson M; Chen Y; Borson S JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058 [TBL] [Abstract][Full Text] [Related]
39. Medicare Coverage of Aducanumab - Implications for State Budgets. Sachs RE; Bagley N N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617 [No Abstract] [Full Text] [Related]
40. What the Aducanumab Approval Reveals About Alzheimer Disease Research. Manly JJ; Glymour MM JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]